Home » Newsletters » BioWorld Asia

BioWorld Asia

Jan. 7, 2004

View Archived Issues

Celltech Details Phase III Trial Plans For CDP870 In Crohn's

A Phase III program in Crohn's disease is under way to evaluate a compound being developed by Celltech Group plc. (BioWorld International) Read More

Innogenetics Forms Hepatitis C Union With Roche Diagnostics

Researchers Find Gene Similar To BRCA1 In Nematode Worm

SkyePharma Disputing GSK's Royalty Payment For Paxil CR

Xenova Gets US$1.5M From Sale Of KSB's Monoclonal Business

Eirx Seeks To Raise £1M Via Initial Public Offering On AIM

U.S. Navy To Evaluate Inovio's DNA Vaccine Delivery System

Other News To Note

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...